Uveal Melanoma Registry (OMNI)
Gathering data to improve clinical practice for uveal melanoma
Uveal melanoma is a rare and aggressive form of ocular melanoma for which there is currently no accepted management or treatment. Uveal melanoma is clinically and biologically different from the more common skin melanoma.
The Uveal Melanoma Registry is currently gathering patient data from sites around Australia, UK and in the USA to identify predictive clinical features, document the natural history of uveal melanoma, and collect real world data regarding its clinical management.
Work is underway to expand the registry, with additional sites planned for Australia and the USA, as well as sites in Germany and Canada.
The registry will help to inform best-practice and improve patient outcomes. It will generate clinical and biomarker data that can be used to support drug development and pricing reimbursement. Patients can also provide direct feedback, offering a holistic view of the impact of uveal melanoma and its treatments.
The Australian arm of the Uveal Melanoma Registry (OMNI) was established by MASC Trials, the Australian Ocular Melanoma Alliance (AOMA) and Pulse Infoframe, together with Dr Richard Carvajal (Columbia University) and Dr Jo Sacco (Liverpool Hospital).
Australian Uveal Melanoma Registry Team
- Prof Anthony Joshua – Coordinating Principal Investigator (PI), Lead Investigator – Australia, PI – St Vincent’s Hospital, VIC
- Dr John McKenzie – PI – Royal Victorian Eye and Ear Hospital, VIC
- Dr Max Conway – PI – Conway Private Rooms, NSW
- Dr Michael Giblin – PI – Chatswood Eye Specialists, NSW
- Dr Timothy Isaacs – PI – Perth Retina, WA
- Dr David Sia – PI – Royal Adelaide Hospital, SA
Trial sites currently recruiting patients
Royal Victorian Eye and Ear Hospital, Melbourne
Recruitment to open soon